The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

Topkan, Erkan; Selek, Uğur; Pehlivan, Berrin; Küçük, Ahmet; Haksöyler, Veysel; Durankus, Nulifer Kilic; Sezen, Duygu; Bölükbaşı, Yasemin

doi:10.2147/jir.s329611

Cited by 6 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, they concluded that PS, response rate, and decreased CA 19-9 serum levels were significant prognostic factors. 39,40 Other studies have found a significantly improved survival in patients with advanced pancreatic tumor who have lower serum CA 19-9 levels, consistent with these findings. 41,42 In contrast, in another study, the tissue over-expression of CA 19-9 in DLBCL NOS was not associated with therapy response or patient survival.…”

Section: Discussionsupporting

confidence: 65%

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression

Foda,

Atia,

Sakr

et al. 2023

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Background: Some epithelial tumors express the carbohydrate antigen 125 (Cancer antigen-125, CA-125) and CA 19-9, especially ovarian and pancreatic tumors. Patients with non-Hodgkin lymphoma (NHL) were reported to have a close association between serum CA-125 levels and adverse prognostic factors with worse survival. We aimed to investigate CA-125 and 19-9 expression in nodal diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS) tissues using immunohistochemistry (IHC) and their relations to clinicopathological manifestations and patients' survival. Methods: 65 cases of DLBCL NOS were examined. A modified mechanical pencil tip was used to construct Manual Tissue Micro-array (TMA) blocks. Immunohistochemical staining for CA-125 and CA 19-9 was performed and scored semi-quantitatively. All relations were analyzed using established statistical methodologies. Results: Aberrant expression of CA 19-9 was detected in 12% of cases without any expression of CA-125. Moreover, 75% of the CA 19-9 positive cases were statistically significantly associated with anemia and performance status 1. Also, 75% of the CA 19-9 positive cases were females. Conclusions: CA 19-9 was aberrantly expressed in 12% of nodal DLBCL NOS cases and significantly related to anaemia and performance status but not to survival. In cases of DLBCL NOS, CA 19-9 expression cannot be considered an independent prognostic factor. CA-125 was not expressed in nodal DLBCL NOS tissues, necessitating re-evaluation studies. Therefore, it is advised to conduct more research to clarify the potential correlation between serum and tissue CA 19-9 levels and other clinic-pathological characteristics of nodal and extranodal DLBCL NOS patients.

show abstract

Section: Discussionsupporting

confidence: 65%

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression

Foda,

Atia,

Sakr

et al. 2023

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

show abstract

“…It was shown that OS and PFS were shorter in PDAC patients with Ca19-9 ≥90 IU/mL than in a group with a Ca19-9 value of <90 IU/mL (PFS: 4.4 vs. 17.0 months, respectively, p < 0.001; OS 7.4 vs. 26.1 months, respectively, p < 0.001). The results confirmed a significant association between elevated Ca19-9 levels and reduced survival results in PDAC patients [46].…”

Section: Ca19-9supporting

confidence: 72%

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Kapszewicz¹,

Małecka-Wojciesko²

2021

JCM

View full text Add to dashboard Cite

A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient concentration in the earliest possible phase of the disease. This review addresses newly selected, simple protein biomarkers—new ones such as thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, and autotaxin and conventional ones such as Ca19-9, inflammatory factors, and coagulation factors. Their possible use in the early detection of PDAC, differentiation from benign diseases, prognosis, and treatment response prediction is discussed. We also address the usefulness of possible combinations of biomarkers in diagnostic panels.

show abstract

“…43 The results of such studies have essentially always confirmed the significant prognostic usefulness of such biological indicators, regardless of the chosen treatment approach. [14][15][16][17][18][19][20][21][22][23][24][25][26] The PIV, a newly discovered relevant indicator of…”

Section: Discussionmentioning

confidence: 99%

“…13 Similarly, growing evidence suggested that chronic systemic inflammation was a key factor underlying the variations in PAC prognoses following similar treatment regimens, regardless of whether the tested index was a single marker or a specific combination. [14][15][16][17][18][19][20][21][22][23][24][25][26] The pan-immune-inflammation index (PIV), a unique blend of circulating platelets, monocytes, neutrophils, and lymphocytes, is another recently developed biomarker. Previous research has found strong links between pretreatment levels of PIV and clinical outcomes in cancers such as colorectal, breast, esophageal, and small-cell lung cancers, Merkel cell carcinomas, and malignant melanomas.…”

Section: Introductionmentioning

confidence: 99%

“…This finding is significant because it demonstrates the presence or emergence of malignant clones that are excessively aggressive, quickly metastatic, and resistant to anti-cancer treatments in the H-PIV group, an unpleasant but typical trait of the highly inflammatory and immune-suppressed tumor phenotypes. 26,46 Despite the fact that all eligible patients underwent an extensive initial staging workup that included FDG-PET-CT, abdominal MRI, and laparoscopic examination (if indicated), uncontrolled widespread DM was the cause of death in 83 (95.4%) of the 87 fatalities in this group. This finding implies that H-PIV patients had occult metastatic foci before the start of C-CRT, which were invisible to conventional staging techniques.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

Topkan¹,

Selek²,

Küçük³

et al. 2022

JIR

Self Cite

View full text Add to dashboard Cite

Objective This study sought to determine whether pretreatment pan-immune-inflammation value (PIV) could be used to predict prognosis in patients with locally advanced pancreatic adenocarcinoma (LA-PAC) following definitive concurrent chemoradiotherapy (C-CRT). Methods The outcomes of 178 LA-PAC patients who received definitive C-CRT were analyzed retrospectively. For all patients, the PIV was calculated using the peripheral blood platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) counts obtained on the first day of C-CRT: PIV=P×M×N÷L. The optimum cutoff values for PIV connected to progression-free (PFS) and overall survival (OS) results were sought using receiver operating characteristic (ROC) curve analysis. The OS and PFS differences between the PIV groups constituted the primary and secondary endpoints, respectively. Results ROC curve analysis indicated that the ideal PIV cutoff was 464 (AUC: 75.9%, sensitivity: 74.1%, specificity: 71.9%), which categorized patients into two groups based on PFS and OS results: low PIV (L-PIV; N = 69) and high PIV (H-PIV; N = 109). According to comparative survival analyses, patients in the L-PIV group had significantly longer median PFS (14.3 vs 7.3 months; HR: 3.04; P<0.001) and OS (25.9 vs 13.3 months; HR: 2.86; P<0.001) than those in the H-PIV group. Although none of the H-PIV patients could survive beyond 5 years, the estimated 5-year OS rate was 29.7% in the L-PIV cohort. In multivariate analyses, besides the L-PIV, N 0 nodal stage, and CA 19–9 ≤ 90 U/mL appeared to be the independent predictors of better PFS (P < 0.05 for each) and OS (P < 0.05 for each) results. Conclusion The present results indicated that pre-C-CRT L-PIV measures were associated with favorable median and long-term PFS and OS results in LA-PAC patients, suggesting that the PIV is a potent and independent novel prognostic biomarker.

show abstract

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

Cited by 6 publications

References 44 publications

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

Contact Info

Product

Resources

About